Bond Barclay PLC 2.75% ( US06741RFH93 ) in USD

Issuer Barclay PLC
Market price 100 %  ▼ 
Country  United Kingdom
ISIN code  US06741RFH93 ( in USD )
Interest rate 2.75% per year ( payment 2 times a year)
Maturity 17/01/2023 - Bond has expired



Prospectus brochure of the bond Barclays PLC US06741RFH93 in USD 2.75%, expired


Minimal amount 1 000 USD
Total amount 247 000 USD
Cusip 06741RFH9
Standard & Poor's ( S&P ) rating N/A
Moody's rating N/A
Detailed description Barclays PLC is a British multinational banking and financial services corporation headquartered in London, offering a wide range of services including personal and corporate banking, investment banking, and wealth management.

The Bond issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06741RFH93, pays a coupon of 2.75% per year.
The coupons are paid 2 times per year and the Bond maturity is 17/01/2023







http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm
424B2 1 a13-1512_13424b2.htm 424B2 - 2 75RETAIL 10Y (NON-CALLABLE)

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered
Maximum Aggregate Offering Price
Amount of Registration Fee(1)







Global Medium-Term Notes, Series A
$247,000
$33.69



(1)
Calculated in accordance with Rule 457(r) of the Securities Act of 1933.


1 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm

Pricing Supplement dated January 14, 2013
Filed Pursuant to Rule 424(b)(2)
(To Prospectus dated August 31, 2010 and
Registration No. 333-169119
the Prospectus Supplement dated May 27, 2011)













US$247,000
2.75% FIXED RATE NOTES DUE JANUARY 17, 2023

Principal Amount:
US$247,000
Issuer:
Barclays Bank PLC

Issue Price:
100%
Series:
Global Medium-Term Notes, Series A

Original Issue Date:
January 17, 2013
Return at Maturity:
If you hold the Notes to maturity, you will receive at
least 100% of your principal, subject to the
creditworthiness of Barclays Bank PLC. The Notes
are not, either directly or indirectly, an obligation of any
third party, and any payment to be made on the Notes,
including any principal protection provided at maturity,
depends on the ability of Barclays Bank PLC to
satisfy its obligations as they come due.

Interest Rate Type:
Fixed Rate
Original Trade Date:
January 14, 2013

Maturity Date:
January 17, 2023
CUSIP:
06741RFH9
ISIN:
US06741RFH93
Denominations:
Minimum denominations of US$1,000 and integral
Business Day:
x
New York

multiples of US$1,000 thereafter.
x
London

o
Euro

o
Other (_________________)


Interest Rate:
2.75% per annum

Interest Payment Dates:
o Monthly, o Quarterly, x Semi-Annual y, o Annual y,
payable in arrears on the 17 day
th
of each January and July, commencing on July 17, 2013 and ending on the Maturity Date or the relevant Survivor's
Option Payment Date, if applicable.

Interest Period:
The initial Interest Period wil begin on, and include, the Original Issue Date and end on, but exclude, the first Interest Payment Date. Each subsequent
Interest Period wil begin on, and include, the Interest Payment Date for the immediately preceding Interest Period and end on, but exclude, the next
fol owing Interest Payment Date. The final Interest Period wil end on, but exclude, the Maturity Date (or the Survivor's Option Payment Date, if applicable).

Survivor's Option:
Upon request by the authorized representative of the beneficial owner of the Notes, we wil repay those Notes prior to the Maturity Date fol owing the death
of the beneficial owner of the Notes, provided such Notes were acquired by the deceased beneficial owner at least six months prior to the date of the
request.
The right to exercise this option wil be subject to:
·
limitations on the aggregate dollar amount of exercises by all holders of the Notes offered by this pricing supplement in any calendar year;

and
·
a maximum permitted dollar amount of an individual exercise with respect to the Notes offered by this pricing supplement by a holder of the

Notes offered by this pricing supplement in any calendar year.
For additional details regarding the Survivor's Option, see "Risk Factors -- Any Exercise of the Survivor's Option May Be Limited in Amount and Any
2 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm
Repayments Made With Respect To a Survivor's Option Wil Not Be Made Immediately" and "Description of Survivor's Option" below.

Business Day Convention:
Fol owing, Unadjusted
Day Count Convention:
30/360

Settlement:
DTC; Book-entry; Transferable.

Listing:
The Notes wil not be listed on any U.S. securities exchange or quotation system.




Price to Public

Agent's Commission

(1)
Proceeds to Barclays Bank PLC
Per Note
100%

1.25%

98.75%
Total
$247,000

$3,087.50

$243,912.50

(1) Barclays Capital Inc. will receive commissions from the Issuer equal to 1.25% of the principal amount of the notes, or $98.75 per $1,000 principal amount, and may retain al or a portion of these commissions or use all
or a portion of these commissions to pay sel ing concessions or fees to other dealers.

The Notes wil not be listed on any U.S. securities exchange or quotation system. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of
these securities or determined that this pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.

We may use this pricing supplement in the initial sale of Notes. In addition, Barclays Capital Inc. or another of our affiliates may use this pricing supplement in market resale transactions in any Notes after
their initial sale. Unless we or our agent informs you otherwise in the confirmation of sale, this pricing supplement is being used in a market resale transaction.

Any payment on the Notes is subject to the creditworthiness of the Issuer and is not guaranteed by any third party. For a description of risks with respect to the ability of Barclays Bank PLC to satisfy its
obligations as they come due, see "Issuer Credit Risk" in this pricing supplement.

Investing in the Notes involves a number of risks. See "Risk Factors" beginning on page S-6 of the prospectus supplement and "Selected Risk Factors" below.

The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC and are not insured by the U.S. Federal
Deposit Insurance Corporation or any other governmental agency of the United States, the United Kingdom or any other jurisdiction.

3 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm


We urge you to consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your advisors have
carefully considered the suitability of an investment in the Notes in light of your particular circumstances.

Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which this pricing supplement relates.
Before you invest, you should read the prospectus dated August 31, 2010, the prospectus supplement dated May 27, 2011, and other documents
Barclays Bank PLC has filed with the SEC for more complete information about Barclays Bank PLC. and this offering. Buyers should rely upon this
pricing supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus for complete details. You may get these
documents and other documents Barclays Bank PLC has filed for free by visiting EDGAR on the SEC website at www.sec.gov, and you may also
access the prospectus and prospectus supplement through the links below:

·
Prospectus dated August 31, 2010:


http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm

·
Prospectus Supplement dated May 27, 2011:


http://www.sec.gov/Archives/edgar/data/312070/000119312511152766/d424b3.htm

Our Central Index Key, or CIK, on the SEC website is 0000312070.

Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this pricing supplement, the
prospectus, the prospectus supplement and any relevant free writing prospectus if you request it by calling your Barclays Capital Inc. sales
representative, such dealer or 1-888-227-2275 (Extension 2-3430). A copy of the prospectus may be obtained from Barclays Capital Inc., 745 Seventh
Avenue--Attn: US InvSol Support, New York, NY 10019.

We reserve the right to change the terms of, or reject any offer to purchase the Notes prior to their issuance. In the event of any changes to the terms of the
Notes, we wil notify you and you wil be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which
case we may reject your offer to purchase.

As used in this term sheet, the "Company," "we," "us," or "our" refers to Barclays Bank PLC.

4 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm

SELECTED RISK FACTORS


An investment in the Notes involves significant risks. You should read the risks summarized below in connection with, and the risks summarized
below are qualified by reference to, the risks described in more detail in the "Risk Factors" section beginning on page S-6 of the prospectus
supplement. We urge you to consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your
advisors have carefully considered the suitability of an investment in the Notes in light of your particular circumstances.

·
Issuer Credit Risk-- The Notes are our unsecured debt obligations, and are not, either directly or indirectly, an obligation of any third party. Any

payment to be made on the Notes, including any principal protection provided at maturity, depends on our ability to satisfy our obligations as they come
due. As a result, the actual and perceived creditworthiness of Barclays Bank PLC may affect the market value of the Notes and, in the event we were to
default on our obligations, you may not receive the principal protection or any other amounts owed to you under the terms of the Notes.

·
Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity--While the payment at maturity described in this

pricing supplement is based on the ful principal amount of your Notes, the original issue price of the Notes includes the agent's commission and the cost
of hedging our obligations under the Notes through one or more of our affiliates. As a result, the price, if any, at which Barclays Capital Inc. and other
affiliates of Barclays Bank PLC wil be wil ing to purchase Notes from you in secondary market transactions wil likely be lower than the price you paid for
your Notes, and any sale prior to the Maturity Date could result in a substantial loss to you.

·
Potential Conflicts--We and our affiliates play a variety of roles in connection with the issuance of the Notes, including hedging our obligations under the

Notes. In performing these duties, the economic interests of our affiliates of ours are potential y adverse to your interests as an investor in the Notes.

In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of the Notes to certain of its clients. In
doing so, Barclays Wealth wil be acting as agent for Barclays Bank PLC and may receive compensation from Barclays Bank PLC in the form of
discounts and commissions. The role of Barclays Wealth as a provider of certain services to such customers and as agent for Barclays Bank PLC in
connection with the distribution of the Notes to investors may create a potential conflict of interest, which may be adverse to such clients. Barclays
Wealth is not acting as your agent or investment adviser, and is not representing you in any capacity with respect to any purchase of Notes by you.
Barclays Wealth is acting solely as agent for Barclays Bank PLC. If you are considering whether to invest in the Notes through Barclays Wealth, we
strongly urge you to seek independent financial and investment advice to assess the merits of such investment.

·
Lack of Liquidity--The Notes wil not be listed on any securities exchange. Barclays Capital Inc. and other affiliates of Barclays Bank PLC intend to

make a secondary market for the Notes but are not required to do so, and may discontinue any such secondary market making at any time, without
notice. Barclays Capital Inc. may at any time hold unsold inventory, which may inhibit the development of a secondary market for the Notes. Even if there
is a secondary market, it may not provide enough liquidity to al ow you to trade or sel the Notes easily. Because other dealers are not likely to make a
secondary market for the Notes, the price at which you may be able to trade your Notes is likely to depend on the price, if any, at which Barclays Capital
Inc. and other affiliates of Barclays Bank PLC are wil ing to buy the Notes. The Notes are not designed to be short-term trading instruments. Accordingly,
you should be able and wil ing to hold your Notes to maturity.

·
Any Exercise of the Survivor's Option May Be Limited in Amount and Any Repayments Made With Respect to a Survivor's Option Will Not Be

Made Immediately -- The Survivor's Option is a provision of the Notes pursuant to which we agree to repay the Notes, if requested by an authorized
representative of the beneficial owner of the Notes, fol owing the death of the beneficial owner of the Notes, provided that the Notes were acquired by the
beneficial owner at least six months prior to the date of the request. Acceptance of an exercise of a Survivor's Option and determinations regarding the
5 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm
eligibility and validity of any exercise of a Survivor's Option wil be at our sole discretion. We also have the discretionary right to apply a limit set to the
aggregate principal amount of Notes as to which exercises of the Survivor's Option wil be accepted by us from all authorized representatives of
deceased beneficial owners of Notes offered by this pricing supplement in any calendar year to an amount equal to 2% of the aggregate principal amount
of Notes offered by this pricing supplement outstanding as of the end of the most recent calendar year. In addition, we have the discretionary

PS-1
6 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm

right to limit to $250,000 the aggregate principal amount of Notes offered by this pricing supplement as to which exercises of the Survivor's Option wil be
accepted by us from the authorized representative of any deceased beneficial owner of the Notes offered by this pricing supplement in any calendar
year. Accordingly, no assurance can be given that the valid exercise of a Survivor's Option, if any, for a desired amount wil be permitted in any single
calendar year. In addition, as a result of the foregoing limitations, in some cases exercises of a Survivor's Option may not result in any payment in the
year that the Survivor's Option has been exercised, or in one or more years subsequent to the year that the Survivor's Option was first
exercised. Furthermore, Survivor's Option claims that were subject to the foregoing limitations in one or more preceding year wil be deemed to be
tendered in a succeeding calendar year (subject to the satisfaction of the conditions specified below, including the submission of a Survivor's Option
Reaffirmation Form (as defined below)) and in such succeeding calendar year wil again be subject to the limitations described above. As a result,
additional Survivor's Option exercises made in any such succeeding calendar year are more likely to be limited by the limitations described above
beca3use the resubmission of the Survivor's Option exercises that were subject to the limitations in preceding years may result in the limitation thresholds
described above being reached earlier in succeeding calendar years. These limitations and our discretion in applying any such limitations are discussed in
more detail under the "Description of the Survivor's Option" below.

If a valid request to exercise the Survivor's Option is not ful y accepted in any calendar year due to the application of any of the limitations described in
the preceding paragraph and in "Description of the Survivor's Option" below, the Notes wil be deemed to be tendered in the fol owing calendar year only
if an authorized representative of the deceased beneficial owner and any Financial Institution (as defined below) through which the beneficial ownership
interest in the Notes is held by the deceased beneficial owner reaffirms the exercise of the Survivor's Option by submitting a Survivor's Option
Reaffirmation Form (as defined below). If a completed Survivor's Option Reaffirmation Form is not submitted to the trustee within 10 business days
fol owing the delivery thereof by the trustee to the relevant Financial Institution through which the beneficial ownership interest in the Notes is held by the
deceased beneficial owner, the election to exercise the Survivor's Option wil be deemed to have been withdrawn. The requirements relating to Survivor's
Option Reaffirmation Forms are described in more detail under the heading "Description of the Survivor's Option" below.

In addition, even if the Notes accepted for repayment pursuant to the valid exercise of a Survivor's Option in a certain calendar year, you wil not receive
immediate repayment. Repayment on Notes so accepted wil only be made on the first of two Survivor's Option Payment Dates (either May 15 or
November 15) that occurs 30 or more calendar days after the date of acceptance.

Whether you should exercise a Survivor's Option if you meet the eligibility requirements to do so is a decision you wil need to make in consultation with
your investment, legal, accounting, tax and other advisers, after considering al the facts and circumstances of your situation. An additional consideration
that you may wish to take into account is the prevailing secondary market prices for the notes, if any, at the time you are considering the exercise of the
Survivor's Option or the submission of a Survivor's Option Reaffirmation Form. In some circumstances, such secondary market prices, if any, may be
greater than the price you would receive upon the exercise of your Survivor's Option. Accordingly, you should contact your advisers to determine the
prevailing secondary market prices of the Notes, if any, in order to determine whether to sel the notes to a market participant at such secondary market
prices, if any, or to exercise the Survivor's Option to receive repayment at a price equal to 100% of the principal amount plus accrued and unpaid interest.

For additional details regarding the Survivor's Option, see "Description of the Survivor's Option" in this pricing supplement.

·
Many Economic and Market Factors Will Impact the Value of the Notes--The value of the Notes wil be affected by a number of economic and

market factors that may either offset or magnify each other, including:

o the time to maturity of the Notes;
o interest and yield rates in the market generally;
o a variety of economic, financial, political, regulatory or judicial events; and
7 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm
o our creditworthiness, including actual or anticipated downgrades in our credit ratings.

PS-2
8 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm

DESCRIPTION OF SURVIVOR'S OPTION

Upon request by the authorized representative of the beneficial owner of the Notes, Barclays Bank PLC wil repay those Notes prior to the Maturity Date fol owing
the death of the beneficial owner of the Notes (the ``Survivor's Option' ), provided such Notes were acquired by the deceased beneficial owner at least six
months prior to the date of the request. Upon the valid exercise of the Survivor's Option and the proper tender of the Notes for repayment, Barclays Bank PLC,
subject to the limitations described below, wil repay such Notes, in whole or in part, at a price equal to 100% of the principal amount of the deceased beneficial
owner's beneficial interest in the Notes plus accrued and unpaid interest to the date of repayment. For purposes of this section, a beneficial owner of Notes is a
person who has the right, immediately prior to such person's death, to receive the proceeds from the disposition of such Notes, as wel as the right to receive
payment of the principal of the Notes.

To be valid, the Survivor's Option must be exercised by or on behalf of the person who has authority to act on behalf of the deceased beneficial owner of the
Notes under the laws of the applicable jurisdiction (including, without limitation, the personal representative of or the executor of the estate of the deceased
beneficial owner or the surviving joint owner with the deceased beneficial owner) (for purposes of this section, the authorized representative of a deceased
beneficial owner shall be referred to as an "Authorized Representative").

The death of a person holding a beneficial ownership interest in the Notes: (1) with any person in a joint tenancy with right of survivorship; or (2) with his or her
spouse in tenancy by the entirety, tenancy in common, as community property or in any other joint ownership arrangement, wil be deemed the death of a
beneficial owner of those Notes, and the entire principal amount of the Notes (subject to the limitations described below) held in this manner wil be subject to
repayment by Barclays Bank PLC upon request. However, the death of a person holding a beneficial ownership interest in Notes as tenant in common with a
person other than his or her spouse wil be deemed the death of a beneficial owner only with respect to such deceased person's interest in the Notes, and only
the deceased beneficial owner's percentage interest in the principal amount of the Notes wil be subject to repayment.

If the ownership interest in the Notes is held by a nominee for a beneficial owner or by a custodian under a Uniform Gifts to Minors Act or Uniform Transfer to
Minors Act, or by a trustee of a trust, or by a guardian or committee for a beneficial owner, the death of the beneficial owner of the Notes wil constitute death of
the beneficial owner for purposes of the Survivor's Option, if the beneficial ownership interest can be established to the satisfaction of Barclays Bank PLC. In
these cases, the death of the nominee, custodian, trustee, guardian or committee wil not be deemed the death of the beneficial owner of the Notes for purposes
of the Survivor's Option.

Notes beneficially owned by a trust wil be regarded as beneficially owned by each beneficiary of the trust to the extent of that beneficiary's interest in the trust
(however, a trust's beneficiaries col ectively cannot be beneficial owners of more Notes than are owned by the trust); provided that the beneficiary has a current
interest in the trust, which may be evidenced by a current right to receive distributions or other proceeds from the trust. The death of a beneficiary of a trust wil
be deemed the death of the beneficial owner of the Notes beneficially owned by the trust to the extent of that beneficiary's interest in the trust; however, only the
death of all such individuals who are tenants by the entirety or joint tenants in a tenancy which is the beneficiary of a trust wil be deemed the death of the
beneficiary of the trust. The death of an individual who was a tenant in common in a tenancy which is the beneficiary of a trust wil be deemed the death of the
beneficiary of the trust only with respect to the deceased holder's beneficial ownership interest in the Notes, unless spouses are the tenants in common, in which
case only the death of both spouses wil be deemed the death of the beneficiary of the trust.

Barclays Bank PLC has the discretionary right to limit the aggregate principal amount of the Notes as to which exercises of the Survivor's Option wil be accepted
by it from al authorized representatives of deceased beneficial owners of Notes offered by this pricing supplement in any calendar year, to an amount equal to
2.0% of the aggregate amount of the Notes offered by this pricing supplement, outstanding as of the end of the most recent calendar year ("Aggregate Put
Limitation").

9 of 27
1/16/2013 12:53 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913002867/a13-1512_13424b2.htm
Barclays Bank PLC also has the discretionary right to limit to $250,000 the aggregate principal amount of Notes offered pursuant to this pricing supplement as to
which exercises of the Survivor's Option wil be accepted by Barclays Bank PLC from the Authorized Representative for any individual deceased beneficial owner
of such Notes in any calendar year ("Individual Put Limitation", and together with the "Aggregate Put Limitation", the "Put Limitations").

In addition, the exercise of the Survivor's Option (a) for a principal amount of less than $1,000 or (b) if such exercise would result in a Note with a principal amount
of less than $1,000 outstanding, wil not be permitted. If, however, the original principal amount of such Notes was less than $1,000, the Authorized
Representative may exercise the Survivor's Option, but only for the ful principal amount of such Note.

PS-3
10 of 27
1/16/2013 12:53 PM